Phase 3 Psoriasis Trial, Recruiting (NCT07672561)

Phase 3 Psoriasis Trial, Recruiting NCT07672561 Sponsor: Zhejiang Wenda Pharma Technology LTD. Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT07672561 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 to 75 years old at the time of signing consent to participate
People who have been diagnosed with plaque psoriasis for at least 6 months before the screening visit
People whose psoriasis covers a significant portion of the body and is rated as moderate to severe by a doctor at both the screening visit and the start of the trial (based on specific skin assessments)

Who may not be able to join:

People whose psoriasis is a type other than plaque psoriasis, such as pustular, guttate, or other forms of the condition
People with uncontrolled high blood pressure, meaning blood pressure readings remain above a certain level after two separate measurements taken while resting (confirm with trial site for exact values)
People with moderate to severe heart failure, classified as Class III or IV under a standard medical rating system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8613787097676

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07672561

Sponsor: Zhejiang Wenda Pharma Technology LTD.

Phase: Phase 3

Status: Recruiting

Condition: Psoriasis

Trial contact: +8613787097676

More information: https://clinicaltrials.gov/study/NCT07672561

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 to 75 years old at the time of signing consent to participate
People who have been diagnosed with plaque psoriasis for at least 6 months before the screening visit
People whose psoriasis covers a significant portion of the body and is rated as moderate to severe by a doctor at both the screening visit and the start of the trial (based on specific skin assessments)

Who may not be able to join:

People whose psoriasis is a type other than plaque psoriasis, such as pustular, guttate, or other forms of the condition
People with uncontrolled high blood pressure, meaning blood pressure readings remain above a certain level after two separate measurements taken while resting (confirm with trial site for exact values)
People with moderate to severe heart failure, classified as Class III or IV under a standard medical rating system

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Zhejiang Wenda Pharma Technology LTD.

Registry

ClinicalTrials.gov

Start date

18 March 2026

Est. completion

30 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Weeks 16; Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov